Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : FDA Takes Steps to Increase Availability of COVID-19 Vaccine

06/14/2021 | 08:26am EDT

Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available.

The agency is announcing today that it is authorizing for use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, two batches of vaccine drug substance manufactured at the Emergent BioSolutions facility in Baltimore. Before making this decision, the FDA conducted a thorough review of facility records and the results of quality testing performed by the manufacturer. Based on this review and considering the current COVID-19 public health emergency, the FDA concluded these batches are suitable for use. While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management.

The FDA's decision to include these two batches of vaccine drug substance in the EUA for the Janssen COVID-19 vaccine means that Janssen vaccine made with this drug substance can be used in the U.S. or exported to other countries. A condition on any export of these batches, or of vaccine manufactured from these batches, is that Janssen and Emergent agree that the FDA may share relevant information about the manufacture of the batches under an appropriate confidentiality agreement, with the regulatory authorities of the countries in which the vaccine may be used.

The FDA has also revised the letter of authorization for the Janssen vaccine to help facilitate potential export to other countries. Under the revised letter of authorization, the distribution and administration of exported vaccines must comply with the laws of the recipient countries.

The FDA has determined several other batches are not suitable for use, but additional batches are still under review and the agency will keep the public informed as those reviews are completed.

Additionally, the FDA has extended the expiration dating for the refrigerated Janssen COVID-19 Vaccine after reviewing information submitted by Janssen and determining that the vaccine can be stored at 2-8 degrees Celsius for 4.5 months instead of 3 months.

'These actions followed an extensive review of records, including the production history of the facility and the testing performed to evaluate the quality of the product. This review has been taking place while Emergent BioSolutions prepares to resume manufacturing operations with corrective actions to ensure compliance with the FDA's current good manufacturing practice requirements,' said Peter Marks, M.D. Ph.D., director of the FDA's Center for Biologics Evaluation and Research. 'Additionally, the action to extend the shelf life for the refrigerated Janssen vaccine means that jurisdictions that have doses on hand now have additional time to administer vaccine.'

The FDA also will keep the public and our global partners informed as we continue to work expeditiously on this issue and will share information when we are able.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Contact:

Media:

FDA Office of Media Affairs

T: 301-796-4540

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
EMERGENT BIOSOLUTIONS INC. 0.35% 62.2 Delayed Quote.-30.76%
JOHNSON & JOHNSON -0.44% 172.64 Delayed Quote.10.15%
All news about JOHNSON & JOHNSON
11:03aJOHNSON & JOHNSON : Vaccine Tourism is Taking Off at SFO; Over 30,000 vaccines a..
AQ
08/04JOHNSON & JOHNSON : FDA - Coronavirus Update
AQ
08/04JOHNSON & JOHNSON : U.S. Govt Donates 151,200 Doses of J&J Vaccines to MoH
AQ
08/04JOHNSON & JOHNSON : 11,000 Tunisian Students Studying Abroad to Receive Covid-19..
AQ
08/03ZYMEWORKS : Says Earned Milestone Payment From Johnson & Johnson Under Licensing..
MT
08/03Johnson & Johnson Appoints Sandipan Ghatak as Head of Consumer Health India C..
CI
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03CORONAVIRUS : AVAT to partner with UNICEF in scaling up vaccine deliveries to Af..
AQ
08/03JOHNSON & JOHNSON : Eyes Ways To Fast-Track COVID-19 Vaccine Delivery To India
MT
08/02JOHNSON & JOHNSON : Janssen Pharmaceutical - UPTRAVI Receives FDA Approval for I..
AQ
More news
Financials (USD)
Sales 2021 94 457 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,3x
Yield 2021 2,40%
Capitalization 456 B 456 B -
EV / Sales 2021 4,84x
EV / Sales 2022 4,62x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 173,36 $
Average target price 184,35 $
Spread / Average Target 6,34%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON10.15%456 367
ROCHE HOLDING AG14.56%340 460
PFIZER, INC.22.77%252 960
ELI LILLY AND COMPANY55.45%237 950
NOVARTIS AG-0.36%223 613
NOVO NORDISK A/S43.21%222 926